Gut adaptation and the glucagon-like peptides

Gut

Volumn 50, Issue 3, 2002, Pages 428-435

  Drucker, D J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE;

APOPTOSIS; ENDOCRINE CELL; HUMAN; IMMUNOREACTIVITY; INTESTINE ABSORPTION; INTESTINE ADAPTATION; INTESTINE EPITHELIUM; INTESTINE INJURY; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; REVIEW; SHORT BOWEL SYNDROME; STOMACH EMPTYING;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINAL DISEASES; INTESTINES; MICE; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS; RATS; SHORT BOWEL SYNDROME;

EID: 0036178672     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.3.428     Document Type: Review

References (94)

1. Molecular size of extractable glucagon and glucagon-like immunoreactivity (GLI) in plasma
2. Characterization of glucagon-like immunoreactivity (GLI)
3. Hamster preproglucagon contains the sequence of glucagon and two related peptides
4. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem
5. The primary structure of porcine glicentin (proglucagon)
6. Bioactive enteroglucagon (oxyntomodulin): Present knowledge on its chemical structure and its biological activities
7. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
8. An enteroglucagon tumour
9. Plasma enteraglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio
10. Intestinal adaptation after jejunoileal bypass in man
11. Small bowel adaptation and its regulation
12. Gut hormones in inflammatory bowel disease
13. The hormonal pattern of intestinal adaptation (a major role for enteroglucagon)
14. Influence of somatostatin and bombesin on plasma enteroglucagon and cell proliferation after intestinal resection in the rat
15. Plasma enteroglucagon and CCK levels and cell proliferation in defunctioned small bowel in the rat
16. Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection
17. Nutrient-independent increases in proglucagon and ornithine decarboxylase messenger RNAs after jejunoileal resection
18. Ileal proglucagon gene expression in the rat: Characterization in intestinal adaptation using in situ hybridization
19. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth
20. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity
21. Plasma enteroglucagon related to malabsorption in coeliac disease
22. Gut-hormone profile in coeliac disease
23. Gut hormone release after intestinal resection
24. Gut hormone responses in subjects with a permanent ileostomy
25. Glucagonoma syndrome demonstrating giant duodenal villi
26. Villous hypertrophy of the small bowel in a patient with glucagonoma
27. Neglected radiologic signs of the glucagonoma syndrome
28. Pre-proglucagon messenger ribonucleic acid: Nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid
29. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine
30. Glucagon gene expression in vertebrate brain
31. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
32. Pancreatic and intestinal processing of proglucagon in man
33. The role of gut-glucagon-like immunoreactants in the control of gastrointestinal epithelial cell renewal
34. Effect of monoclonal antibodies to enteroglucagon on ileal adaptation after proximal small bowel resection
35. Trophic effect of glucagon-(1-21)-peptide on the isolated rat ileal mucosal cells
36. Glucagon 1-21 reduces intestinal epithelial cell proliferation in parenterally fed rats
37. Humoral regulation of intestinal adaptation
38. Comparison of the effects of transforming growth factor alpha and epidermal growth factor on gastrointestinal proliferation and hormone release
39. Effects of keratinocyte growth factor (KGF) on gut growth and repair
40. Induction of intestinal epithelial proliferation by glucagon-like peptide 2
41. Anglerfish islet pre-proglucagon II
42. Trout and chicken proglucagon: Alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2
43. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
44. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide 2
45. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans
46. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
47. Structure, measurement, and secretion of human glucagon-like peptide-2
48. In vivo and in vitro degradation of glucagon-like peptide-2 in humans
49. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV
50. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice
51. Intestinal response to growth factors administered alone or in combination with h[Gly2]-glucagon-like peptide 2
52. Enteroglucagon
53. The glucagon-like peptides
54. Intestinal growth is associated with elevated levels of glucagon-like peptide-2 in diabetic rats
55. Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: Effects of dietary fibre
56. Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes
57. Renal catabolism of human glucagon-like peptides 1 and 2
58. Enzymatic and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in the rat
59. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
60. Impaired meal-stimulated glucagon-like peptide-2 response in ileal resected short bowel patients with intestinal failure
61. Biological determinants of intestinotrophic properties of GLP-2 in vivo
62. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice
63. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2
64. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo
65. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport
66. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
67. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs
68. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2
69. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse
70. Prevention of parenteral nutrition-induced gut hyoplasia by coinfusion of glucagon-like peptide-2
71. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: Effects of glucagon-like peptide 2
72. Time-dependent intestinal adaptation and GLP-2 alterations after small bowel resection in rats
73. GLP-2 augments the adaptive response to massive intestinal resection in rat
74. Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis
75. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion
76. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2
77. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis
78. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor
79. Giucagon-like peptide 2: A new treatment for chemotherapy-induced enteritis
80. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2
81. Enteroendocrine localization of GLP-2 receptor expression
82. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor
83. Structural determinants for activity of glucagon-like peptide-2
84. Signaling mechanisms of glucagon-like peptide 2-induced intestinal epithelial cell proliferation
85. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway
86. Modulation of specific intestinal epithelial progenitors by enteric neurons
87. Glucagon-like peptide-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling
88. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake
89. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine
90. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis
91. Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription
92. GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs
93. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
94. The glucagon-like peptides